| scholarly article | Q13442814 |
| P2093 | author name string | Yanling Liu | |
| P2860 | cites work | Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer | Q38616693 |
| Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint | Q38748101 | ||
| New developments in prostate cancer biomarkers | Q38773948 | ||
| Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. | Q39766437 | ||
| Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment | Q40281409 | ||
| A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy | Q40363294 | ||
| Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. | Q40368993 | ||
| A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays. | Q40445184 | ||
| Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer | Q41195275 | ||
| Drug-diagnostics co-development in oncology | Q41883789 | ||
| A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer | Q42522113 | ||
| Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. | Q46882539 | ||
| Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. | Q51596197 | ||
| Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. | Q52959809 | ||
| Global methylation profiling for risk prediction of prostate cancer. | Q53168600 | ||
| Predictive models for newly diagnosed prostate cancer patients | Q84912363 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer | Q24569630 | ||
| Outcomes of localized prostate cancer following conservative management | Q24647380 | ||
| Circulating biomarkers to monitor cancer progression and treatment | Q26745985 | ||
| Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer | Q26795625 | ||
| Molecular landscape of prostate cancer: implications for current clinical trials | Q26799585 | ||
| Overdiagnosis and overtreatment of prostate cancer | Q26859596 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 | ||
| PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer | Q33565650 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects | Q33657876 | ||
| Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer | Q33723651 | ||
| Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer | Q33775723 | ||
| Targeted deep resequencing of the human cancer genome using next-generation technologies | Q33849791 | ||
| Copy number alteration burden predicts prostate cancer relapse | Q34002312 | ||
| Single-cell genome sequencing: current state of the science | Q34045945 | ||
| Molecular pathways: targeting ETS gene fusions in cancer | Q34135434 | ||
| Noncoding RNAs as novel biomarkers in prostate cancer | Q34176890 | ||
| Circulating tumor cells as biomarkers in prostate cancer | Q34193303 | ||
| Pre-treatment risk stratification of prostate cancer patients: A critical review | Q34268868 | ||
| Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression | Q34397291 | ||
| Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death | Q34424612 | ||
| Drug resistance in cancer: an overview. | Q34437369 | ||
| PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. | Q34468270 | ||
| The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc | Q34558930 | ||
| Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer | Q34577447 | ||
| The Molecular Taxonomy of Primary Prostate Cancer | Q34674332 | ||
| Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. | Q34962331 | ||
| A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants | Q35018146 | ||
| TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers | Q35088099 | ||
| Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression | Q35154249 | ||
| Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. | Q35256915 | ||
| An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples | Q35680291 | ||
| Haplotyping germline and cancer genomes with high-throughput linked-read sequencing | Q35909792 | ||
| Molecular biomarker in prostate cancer: the role of CpG island hypermethylation | Q35952789 | ||
| Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies | Q36022437 | ||
| Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer | Q36075018 | ||
| DNA methylation based biomarkers in non-invasive cancer screening | Q36095878 | ||
| Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing. | Q36160576 | ||
| SPOP mutation leads to genomic instability in prostate cancer. | Q36210354 | ||
| Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer | Q36241242 | ||
| Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation | Q36695645 | ||
| Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis | Q36886346 | ||
| A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer | Q36887707 | ||
| DNA microarrays: a powerful genomic tool for biomedical and clinical research. | Q36895246 | ||
| Targeted RNA sequencing reveals the deep complexity of the human transcriptome | Q37009455 | ||
| Molecular pathogenesis and progression of prostate cancer | Q37055715 | ||
| Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification | Q37067529 | ||
| Beyond PSA: the next generation of prostate cancer biomarkers | Q37238101 | ||
| Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. | Q37435181 | ||
| An expression signature at diagnosis to estimate prostate cancer patients' overall survival | Q37578965 | ||
| ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review). | Q37988318 | ||
| A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer | Q38124252 | ||
| Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine | Q38188730 | ||
| New biomarkers in prostate cancer | Q38202126 | ||
| Androgens and androgen receptor signaling in prostate tumorigenesis. | Q38263398 | ||
| Role of epithelial mesenchymal transition in prostate tumorigenesis | Q38288544 | ||
| A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth | Q38299437 | ||
| Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity | Q38400993 | ||
| Treatment of mCRPC in the AR-axis-targeted therapy-resistant state | Q38535099 | ||
| Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies | Q38551466 | ||
| P433 | issue | 5 | |
| P921 | main subject | genomics | Q222046 |
| personalized medicine | Q2072214 | ||
| P304 | page(s) | 3347-3353 | |
| P577 | publication date | 2017-03-24 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | The context of prostate cancer genomics in personalized medicine | |
| P478 | volume | 13 |
Search more.